Clinical Laboratory Improvement Advisory Committee, 3709 [05-1390]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 16 / Wednesday, January 26, 2005 / Notices
have access to the smallpox virus and
attempt to use it against the American
public and U.S. Government facilities
abroad.
II. Amendment of Declaration
I, Claude A. Allen, Acting Secretary of
the Department of Health and Human
Services, have concluded, in accordance
with the authority vested in me under
section 224(p)(2)(A) of the Public Health
Service Act, that a potential bioterrorist
incident makes it advisable to extend
the January 24, 2003 declaration, as
amended, regarding administration of
smallpox countermeasures until and
including January 23, 2006. The January
24, 2003, declaration, as amended, may
be further amended as circumstances
require.
III. Effective Dates
This extension is effective January 24,
2005 until and including January 23,
2006. The effective period may be
extended or shortened by subsequent
amendment to the January 24, 2003,
declaration.
Dated: January 21, 2005.
Claude A. Allen,
Acting Secretary.
[FR Doc. 05–1479 Filed 1–25–05; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Public Law 92–463), the Centers for
Disease Control and Prevention (CDC)
announces the following committee
meeting.
Name: Clinical Laboratory Improvement
Advisory Committee (CLIAC).
Times and Dates:
8:30 a.m.–5 p.m., February 16, 2005.
8:30 a.m.–3 p.m., February 17, 2005.
Place: Doubletree Hotel (Atlanta/
Buckhead), 3342 Peachtree Rd. NE., Atlanta,
Georgia 30326, Telephone: (404) 231–1234.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 100 people.
Purpose: This committee is charged with
providing scientific and technical advice and
guidance to the Secretary of Health and
Human Services, the Assistant Secretary for
Health, and the Director, CDC, regarding the
need for, and the nature of, revisions to the
standards under which clinical laboratories
are regulated; the impact on medical and
laboratory practice of proposed revisions to
VerDate jul<14>2003
19:33 Jan 25, 2005
Jkt 205001
the standards; and the modification of the
standards to accommodate technological
advances.
Matters To Be Discussed: The agenda will
include updates from the Food and Drug
Administration, the Centers for Medicare &
Medicaid Services, and the Centers for
Disease Control and Prevention;
implementation of cytology proficiency
testing for individuals; a report from the
CLIAC Workgroup on Good Laboratory
Practices for Waived Testing, and discussion
of the Workgroup’s proposals related to such;
and an introduction to appropriate quality
control for diverse and evolving test systems,
including microbiology identification
systems. Agenda items are subject to change
as priorities dictate.
Providing Oral or Written Comments: It is
the policy of CLIAC to accept written public
comments and provide a brief period for oral
public comments whenever possible. Oral
Comments: In general, each individual or
group requesting to make an oral
presentation will be limited to a total time of
five minutes (unless otherwise indicated).
Speakers must also submit their comments in
writing for inclusion in the meeting’s
Summary Report. To assure adequate time is
scheduled for public comments, individuals
or groups planning to make an oral
presentation should, when possible, notify
the contact person below at least one week
prior to the meeting date. Written Comments:
For individuals or groups unable to attend
the meeting, CLIAC accepts written
comments until the date of the meeting
(unless otherwise stated). However, the
comments should be received at least one
week prior to the meeting date so that the
comments may be made available to the
Committee for their consideration and public
distribution. Written comments, one hard
copy with original signature, should be
provided to the contact person below.
Written comments will be included in the
meeting’s Summary Report.
Contact Person for Additional Information:
Rhonda Whalen, Chief, Laboratory Practice
Standards Branch, Division of Laboratory
Systems, Office of Public Health
Partnerships, CDC, 4770 Buford Highway,
NE, Mailstop F–11, Atlanta, Georgia 30341–
3717; telephone (770) 488–8042; fax (770)
488–8279; or via e-mail at RWhalen@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register Notices
pertaining to announcements of meetings and
other committee management activities, for
CDC and the Agency for Toxic Substances
and Disease Registry.
Dated: January 20, 2005.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 05–1390 Filed 1–25–05; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
3709
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Public Law 92–463), the Centers for
Disease Control and Prevention (CDC)
announce the following Federal
Committee meeting.
Name: Advisory Committee on
Immunization Practices (ACIP).
Times and Dates:
8 a.m.–6:30 p.m., February 10, 2005.
8 a.m.–4:30 p.m., February 11, 2005.
Place: Atlanta Marriott Century Center,
2000 Century Boulevard, N.E., Atlanta,
Georgia 30345–3377.
Status: Open to the public, limited only by
the space available.
Purpose: The Committee is charged with
advising the Director, CDC, on the
appropriate uses of immunizing agents. In
addition, under 42 U.S.C. 1396s, the
Committee is mandated to establish and
periodically review and, as appropriate,
revise the list of vaccines for administration
to vaccine-eligible children through the
Vaccines for Children (VFC) program, along
with schedules regarding the appropriate
periodicity, dosage, and contraindications
applicable to the vaccines.
Matters To Be Discussed: The agenda will
include discussions on Hepatitis B vaccine
recommendations; recommendations of use
of Hepatitis A vaccine; Human Papilloma
Virus vaccine working group update;
Meningococcal conjugate vaccine and
possible VFC vote on meningococcal vaccine
use if the vaccine is licensed; varicella
prevention; influenza vaccine
recommendations for 2005; pertussis vaccine
booster dose policy; polio outbreak response
and stockpile planning; revisions to the
general recommendations; yellow fever
vaccine safety work group update; proposal
for use of Evidence-based recommendations;
rotavirus vaccine update; and Departmental
updates.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Demetria Gardner, Epidemiology and
Surveillance Division, National
Immunization Program, CDC, 1600 Clifton
Road, NE., (E–61), Atlanta, Georgia 30333,
telephone (404) 639–8096, fax (404) 639–
8616.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both the CDC and ATSDR.
E:\FR\FM\26JAN1.SGM
26JAN1
]]>Agencies
[Federal Register Volume 70, Number 16 (Wednesday, January 26, 2005)]
[Notices]
[Page 3709]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-1390]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Public Law 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following committee meeting.
Name: Clinical Laboratory Improvement Advisory Committee
(CLIAC).
Times and Dates:
8:30 a.m.-5 p.m., February 16, 2005.
8:30 a.m.-3 p.m., February 17, 2005.
Place: Doubletree Hotel (Atlanta/Buckhead), 3342 Peachtree Rd.
NE., Atlanta, Georgia 30326, Telephone: (404) 231-1234.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 100 people.
Purpose: This committee is charged with providing scientific and
technical advice and guidance to the Secretary of Health and Human
Services, the Assistant Secretary for Health, and the Director, CDC,
regarding the need for, and the nature of, revisions to the
standards under which clinical laboratories are regulated; the
impact on medical and laboratory practice of proposed revisions to
the standards; and the modification of the standards to accommodate
technological advances.
Matters To Be Discussed: The agenda will include updates from
the Food and Drug Administration, the Centers for Medicare &
Medicaid Services, and the Centers for Disease Control and
Prevention; implementation of cytology proficiency testing for
individuals; a report from the CLIAC Workgroup on Good Laboratory
Practices for Waived Testing, and discussion of the Workgroup's
proposals related to such; and an introduction to appropriate
quality control for diverse and evolving test systems, including
microbiology identification systems. Agenda items are subject to
change as priorities dictate.
Providing Oral or Written Comments: It is the policy of CLIAC to
accept written public comments and provide a brief period for oral
public comments whenever possible. Oral Comments: In general, each
individual or group requesting to make an oral presentation will be
limited to a total time of five minutes (unless otherwise
indicated). Speakers must also submit their comments in writing for
inclusion in the meeting's Summary Report. To assure adequate time
is scheduled for public comments, individuals or groups planning to
make an oral presentation should, when possible, notify the contact
person below at least one week prior to the meeting date. Written
Comments: For individuals or groups unable to attend the meeting,
CLIAC accepts written comments until the date of the meeting (unless
otherwise stated). However, the comments should be received at least
one week prior to the meeting date so that the comments may be made
available to the Committee for their consideration and public
distribution. Written comments, one hard copy with original
signature, should be provided to the contact person below. Written
comments will be included in the meeting's Summary Report.
Contact Person for Additional Information: Rhonda Whalen, Chief,
Laboratory Practice Standards Branch, Division of Laboratory
Systems, Office of Public Health Partnerships, CDC, 4770 Buford
Highway, NE, Mailstop F-11, Atlanta, Georgia 30341-3717; telephone
(770) 488-8042; fax (770) 488-8279; or via e-mail at
RWhalen@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining
to announcements of meetings and other committee management
activities, for CDC and the Agency for Toxic Substances and Disease
Registry.
Dated: January 20, 2005.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 05-1390 Filed 1-25-05; 8:45 am]
BILLING CODE 4163-18-P
